Metrics as of 10/16/2026, 08:35 AM (Berlin time), refresh in progress.
Nephros Stock
Nephros, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Robert Banks
- Employees
- 36
- Market cap
- $38 M
- IPO
- 21/09/2004
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within…
Nephros stock: price history
1D
-0.3%
1W
+6.7%
1M
-18.2%
6M
+19.0%
YTD
-28.1%
1Y
-36.1%
2Y
+140.4%
5Y
-54.8%
10Y
+30.0%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~24% weaker price swings than usual
Ask the agents about Nephros
Analyst assessment of Nephros
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 08/08/2025
Nephros stock metrics
P/E
21.84
P/B
3.18
EV/EBITDA
18.89
RETURN ON EQUITY
10.0%
NET MARGIN
19.9%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.5%
FLOAT SHARES
8,745,454
AVG. DAILY VOLUME (30D)
33,237
Insider transactions (SEC)
WEXFORD CAPITAL LP
Amron Arthur H
Amron Arthur H
WEXFORD CAPITAL LP
Amron Arthur H
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Nephros stock
What does Nephros do?
Nephros, Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Robert Banks, the company employs around 36 people.
The IPO was on 21/09/2004; the stock trades on NASDAQ under the ticker NEPH.
What do analysts say about Nephros stock?
4 analysts rate the stock, the consensus is Buy (as of 08/08/2025).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Nephros report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -24% stronger than usual.
Does Nephros pay a dividend?
No, Nephros currently does not pay a dividend.
Which stocks are comparable to Nephros?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Nephros stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nephros against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.